Arbaclofen placarbil

Arbaclofen placarbil (/ɑːrˈbækloʊfɛn pləˈkɑːrbɪl/ ar-BAK-loh-fen plə-KAR-bil, also known as XP19986) is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.[1]

Arbaclofen placarbil
Clinical data
Pregnancy
category
  • N/A
ATC code
  • none
Legal status
Legal status
  • Development terminated
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.221.150
Chemical and physical data
FormulaC19H26ClNO6
Molar mass399.86 g/mol g·mol−1
3D model (JSmol)

It is being developed as an addiction medicine to treat alcoholism. [2]

See also

References
  1. "Archived copy". Archived from the original on 2013-12-02. Retrieved 2013-06-03.CS1 maint: archived copy as title (link)
  2. https://inews.co.uk/essentials/news/business/pill-replaces-alcohol-aims-end-middle-class-drinking-epidemic/


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.